This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.

From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.

Health experts from around the world met November 29 to discuss ways to tackle an emerging crisis.

Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.

The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.

The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.

Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.